Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma
Eur J Cancer
.
2023 Oct:192:113255.
doi: 10.1016/j.ejca.2023.113255.
Epub 2023 Aug 16.
Authors
Rachel S Goodman
1
,
Joy Justice
2
,
Laura J Gardner
3
,
Reena Singh
4
,
Anna K Dewan
5
,
Douglas B Johnson
6
Affiliations
1
Vanderbilt University School of Medicine, Nashville, Tennessee, US. Electronic address:
[email protected]
.
2
Vanderbilt University School of Medicine, Nashville, Tennessee, US. Electronic address:
[email protected]
.
3
Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, US. Electronic address:
[email protected]
.
4
Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, US. Electronic address:
[email protected]
.
5
Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, US. Electronic address:
[email protected]
.
6
Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, US. Electronic address:
[email protected]
.
PMID:
37595488
PMCID:
PMC10900129
DOI:
10.1016/j.ejca.2023.113255
No abstract available
Publication types
Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Melanoma* / drug therapy
Melanoma, Cutaneous Malignant
Skin Neoplasms* / drug therapy
Grants and funding
R01 CA227481/CA/NCI NIH HHS/United States
R01 HL155990/HL/NHLBI NIH HHS/United States